Clicky

RAPT Therapeutics, Inc.(RAPT) News

Date Title
Sep 29 RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now
Sep 25 RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability
Jun 21 Should You Sell Your Stake in RAPT Therapeutics (RAPT)?
Jun 14 Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround
May 13 Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks
May 12 Here's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation
May 10 RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview
May 9 What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
May 9 RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials
May 9 RAPT Therapeutics Reports First Quarter 2024 Financial Results
Apr 9 RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Apr 9 3 Biotech Stocks to Dump Before They Go to Zero
Mar 22 What Makes RAPT Therapeutics (RAPT) an Investment Choice?
Mar 7 Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
Mar 7 RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Mar 5 RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Feb 20 Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests
Feb 20 RAPT Therapeutics Stock Is Down 63%. FDA Halts 2 Studies After Liver Failure.
Feb 20 UPDATE 1-FDA puts on hold two Rapt Therapeutics mid-stage drug trials
Feb 20 RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon